Delving into the Latest Updates on RAS Lifesciences Pvt Ltd. with Synapse

作者: Choudhary, Manish Chandra ; Kazim, Syed N ; Natarajan, Vidhya ; Sharma, Shvetank ; Gupta, Ekta ; Sarin, Shiv K ; Kumar, M Shesheer ; Pandey, Priyanka ; Tripathi, Rachana

BACKGROUNDRecent emphasis in Hepatitis C virus (HCV) evolutionary biology has focused on analysis using Core, E1/E2 and/or NS5b regions, with limited appreciation of full length genome. While HCV genotypes have been described as endemic in the Indian subcontinent, there has been no confirmation at the molecular evolutionary level of these genotypes. We have attempted here to determine the status of Indian HCV genotype 3a sequences in relation to similar genotypes from other parts of the world.METHODSCloning, sequencing and molecular characterization was performed on 9 Indian sequences and comparative analyses were performed with 46 sequences from other countries. Evolutionary-rate and molecular-clock hypothesis testing was addressed by Bayesian MCMC.RESULTSGenetic analysis of full length genome revealed two hypervariable regions (HVR) in E2 region - HVR496 and HVR576, with a variable 5-8 amino-acid insertion sequence and a putative N-glycosylation site. Phylogenetic analysis revealed a divergence resulting in 2 distinct clades: clade-1 represented by HCV 3a subtype and clade-2 represented by other 3 subtype genomes. Clade-2 shows earlier divergence than clade-1. Analysis revealed that genotype 3a genomes from India roots out first (∼99 years ago) in clade1. Bayesian skyline plot analysis revealed an increase in effective number of infections from 1940s to 1990s, followed by a gradual decrease after 2000.CONCLUSIONSGenotype 3a sequences appear to have originated in India and later dispersed to United Kingdom around mid 1940s, most likely around the time of Indian independence and World War II.

100 项与 RAS Lifesciences Pvt Ltd. 相关的药物交易

登录后查看更多信息

100 项与 RAS Lifesciences Pvt Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月14日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

批准上市

3

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

人表皮生长因子 (RAS Lifesciences Pvt Ltd.) ( EGFR )	-	批准上市
组织纤溶酶原激活物（tPA）生物类似药(RAS Lifesciences Pvt Ltd.) ( PLG )	血栓形成更多	批准上市
非格司亭生物类似药(RAS Lifesciences Pvt Ltd.) ( CSF-3R )	中性粒细胞减少更多	批准上市